M., Pool, J
The researchers reported higher MTT assay signals, more cell movement, more tube-like network formation, higher VEGF-A expression, and increased ERK1/2 phosphorylation after BPC-157 exposure
Its small size confers favorable physicochemical properties for solubility, stability, and intranasal or subcutaneous delivery, but also raises questions about specificity that are common to short peptides in vivo proteolytic stability, off-target binding, and minimum receptor recognition motif identification all require additional characterization that the published literature does not yet fully provide
Stable Gastric Pentadecapeptide BPC 157 in Trials for Inflammatory Bowel Disease (PL-10, PLD-116, PL 14736, Pliva) Current Pharmaceutical Design Comprehensive review of BPC 157 clinical development for inflammatory bowel disease including ulcerative colitis trials, demonstrating mucosal healing and anti-inflammatory effects across multiple organ systems
Ready to take control of your biological age